Liquidia Q2 FY26 net income swings to $74.7 million; net product sales rise 31% from Q1 to $170.4 million - LQDA News | RalliesLiquidia Q2 FY26 net income swings to $74.7 million; net product sales rise 31% from Q1 to $170.4 million
L
LQDA• Product uptake and pipeline update
- YUTREPIA logged about 5,900 unique prescriptions since its June 2025 launch.
- CEO Roger Jeffs cited sustained adoption, with about 5,000 patients started.
- Liquidia activated sites and began enrollment for L606’s Re-Spire study.
Quarterly results and sales growth
- Liquidia swung to GAAP net income of $74.7 million, or $0.84 per basic share and $0.74 per diluted share.
- Net product sales rose to $170.4 million, driven by higher YUTREPIA volume; service revenue slipped to $1.3 million.
- Non-GAAP adjusted EBITDA climbed to $96.3 million, marking a fourth straight quarter of improving profitability.
- Cash and cash equivalents increased to $284.2 million.
